Skip to main content
Top
Published in: Malaria Journal 1/2018

Open Access 01-12-2018 | Research

Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts

Authors: Motohiro Nonaka, Yuho Murata, Ryo Takano, Yongmei Han, Md. Hazzaz Bin Kabir, Kentaro Kato

Published in: Malaria Journal | Issue 1/2018

Login to get access

Abstract

Background

Malaria is a major infectious disease in the world. In 2015, approximately 212 million people were infected and 429,000 people were killed by this disease. Plasmodium falciparum, which causes falciparum malaria, is becoming resistant to artemisinin (ART) in Southeast Asia; therefore, new anti-malarial drugs are urgently needed. Some excellent anti-malarial drugs, such as quinine or ART, were originally obtained from natural plants. Hence, the authors screened a natural product library comprising traditional Chinese medicines (TCMs) to identify compounds/extracts with anti-malarial effects.

Methods

The authors performed three assays: a malaria growth inhibition assay (GIA), a cytotoxicity assay, and a malaria stage-specific GIA. The malaria GIA revealed the anti-malarial ability and half-maximal inhibitory concentrations (IC50) of the natural products, whereas the malaria stage-specific GIA revealed the point in the malaria life cycle where the products exerted their anti-malarial effects. The toxicity of the products to the host cells was evaluated with the cytotoxicity assay.

Results

Four natural compounds (berberine chloride, coptisine chloride, palmatine chloride, and dehydrocorydaline nitrate) showed strong anti-malarial effects (IC50 < 50 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain. Two natural extracts (Phellodendri cortex and Coptidis rhizoma) also showed strong antiplasmodial effects (IC50 < 1 µg/ml), and low cytotoxicity (cell viability > 80%). These natural products also demonstrated anti-malarial capability during the trophozoite and schizont stages of the malaria life cycle.

Conclusions

The authors identified four compounds (berberine chloride, coptisine chloride, palmatine chloride, and dehydrocorydaline nitrate) and two extracts (Phellodendri cortex and Coptidis rhizoma) with anti-malarial activity, neither of which had previously been described. The IC50 values of the compounds were comparable to that of chloroquine and better than that of pyrimethamine. These compounds and extracts derived from TCMs thus show promise as potential future anti-malarial drugs.
Literature
1.
go back to reference WHO. World malaria report 2016. Geneva: World Health Organization; 2016. WHO. World malaria report 2016. Geneva: World Health Organization; 2016.
2.
go back to reference Singh B, Kim Sung L, Matusop A, Radhakrishnan A, Shamsul SSG, Cox-Singh J, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet. 2004;363:1017–24.CrossRefPubMed Singh B, Kim Sung L, Matusop A, Radhakrishnan A, Shamsul SSG, Cox-Singh J, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet. 2004;363:1017–24.CrossRefPubMed
4.
go back to reference Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med. 2017;7:025619.CrossRef Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med. 2017;7:025619.CrossRef
5.
go back to reference Schlitzer M. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem. 2007;2:944–86.CrossRefPubMed Schlitzer M. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem. 2007;2:944–86.CrossRefPubMed
6.
7.
go back to reference Recuenco FC, Kobayashi K, Ishiwa A, Enomoto-Rogers Y, Fundador NGV, Sugi T, et al. Gellan sulfate inhibits Plasmodium falciparum growth and invasion of red blood cells in vitro. Sci Rep. 2014;4:4723.CrossRefPubMedPubMedCentral Recuenco FC, Kobayashi K, Ishiwa A, Enomoto-Rogers Y, Fundador NGV, Sugi T, et al. Gellan sulfate inhibits Plasmodium falciparum growth and invasion of red blood cells in vitro. Sci Rep. 2014;4:4723.CrossRefPubMedPubMedCentral
8.
go back to reference Skinner TS, Manning LS, Johnston WA, Davis TM. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasitol. 1996;26:519–25.CrossRefPubMed Skinner TS, Manning LS, Johnston WA, Davis TM. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasitol. 1996;26:519–25.CrossRefPubMed
9.
go back to reference Kiara SM, Okombo J, Masseno V, Mwai L, Ochola I, Borrmann S, et al. In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan Coast: emergence of parasites with Ile-164-Leu mutation. Antimicrob Agents Chemother. 2009;53:3793–8.CrossRefPubMedPubMedCentral Kiara SM, Okombo J, Masseno V, Mwai L, Ochola I, Borrmann S, et al. In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan Coast: emergence of parasites with Ile-164-Leu mutation. Antimicrob Agents Chemother. 2009;53:3793–8.CrossRefPubMedPubMedCentral
10.
go back to reference Okombo J, Kiara SM, Rono J, Mwai L, Pole L, Ohuma E, et al. In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya. Antimicrob Agents Chemother. 2010;54:3302–7.CrossRefPubMedPubMedCentral Okombo J, Kiara SM, Rono J, Mwai L, Pole L, Ohuma E, et al. In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya. Antimicrob Agents Chemother. 2010;54:3302–7.CrossRefPubMedPubMedCentral
11.
go back to reference Iwasa K, Kim HS, Wataya Y, Lee DU. Antimalarial activity and structure-activity relationships of protoberberine alkaloids. Eur J Med Chem. 1998;33:65–9.CrossRef Iwasa K, Kim HS, Wataya Y, Lee DU. Antimalarial activity and structure-activity relationships of protoberberine alkaloids. Eur J Med Chem. 1998;33:65–9.CrossRef
12.
go back to reference Iwasa K, Nishiyama Y, Ichimaru M, Moriyasu M, Kim H-S, Wataya Y, et al. Structure-activity relationships of quaternary protoberberine alkaloids having an antimalarial activity. Eur J Med Chem. 1999;34:1077–83.CrossRef Iwasa K, Nishiyama Y, Ichimaru M, Moriyasu M, Kim H-S, Wataya Y, et al. Structure-activity relationships of quaternary protoberberine alkaloids having an antimalarial activity. Eur J Med Chem. 1999;34:1077–83.CrossRef
13.
go back to reference Hayase H, Watanabe N, Lim CL, Nogawa T, Komatsuya K, Kita K, et al. Inhibition of malaria parasite growth by quinomycin A and its derivatives through DNA-intercalating activity. Biosci Biotechnol Biochem. 2015;79:633–5.CrossRefPubMed Hayase H, Watanabe N, Lim CL, Nogawa T, Komatsuya K, Kita K, et al. Inhibition of malaria parasite growth by quinomycin A and its derivatives through DNA-intercalating activity. Biosci Biotechnol Biochem. 2015;79:633–5.CrossRefPubMed
14.
go back to reference Silikas N, Mccall DLC, Sharples D, Watkins WM, Waigh RD, Barber J. The antimalarial activity of berberine and some synthetic analogues. Pharm Pharmacol Commun. 1996;2:55–8. Silikas N, Mccall DLC, Sharples D, Watkins WM, Waigh RD, Barber J. The antimalarial activity of berberine and some synthetic analogues. Pharm Pharmacol Commun. 1996;2:55–8.
15.
go back to reference Wright CW, Marshall SJ, Russell PF, Anderson MM, Phillipson JD, Kirby GC, et al. In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids. J Nat Prod. 2000;63:1638–40.CrossRefPubMed Wright CW, Marshall SJ, Russell PF, Anderson MM, Phillipson JD, Kirby GC, et al. In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids. J Nat Prod. 2000;63:1638–40.CrossRefPubMed
16.
go back to reference Grycová L, Dostál J, Marek R. Quaternary protoberberine alkaloids. Phytochemistry. 2007;68:150–75.CrossRefPubMed Grycová L, Dostál J, Marek R. Quaternary protoberberine alkaloids. Phytochemistry. 2007;68:150–75.CrossRefPubMed
17.
go back to reference Marek R, Seckárová P, Hulová D, Marek J, Dostál J, Sklenár V. Palmatine and berberine isolation artifacts. J Nat Prod. 2003;66:481–6.CrossRefPubMed Marek R, Seckárová P, Hulová D, Marek J, Dostál J, Sklenár V. Palmatine and berberine isolation artifacts. J Nat Prod. 2003;66:481–6.CrossRefPubMed
18.
go back to reference Parida P, Kalita S, Yadav RNS, Shankar B. Homology modeling and docking studies of Plasmodium falciparum telomerase reverse transcriptase with berberine and some of its derivatives. Bangladesh J Pharmacol. 2014;9:96–104. Parida P, Kalita S, Yadav RNS, Shankar B. Homology modeling and docking studies of Plasmodium falciparum telomerase reverse transcriptase with berberine and some of its derivatives. Bangladesh J Pharmacol. 2014;9:96–104.
19.
go back to reference Sriwilaijareon N, Petmitr S, Mutirangura A, Ponglikitmongkol M, Wilairat P. Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002;51:99–103.CrossRefPubMed Sriwilaijareon N, Petmitr S, Mutirangura A, Ponglikitmongkol M, Wilairat P. Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002;51:99–103.CrossRefPubMed
Metadata
Title
Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts
Authors
Motohiro Nonaka
Yuho Murata
Ryo Takano
Yongmei Han
Md. Hazzaz Bin Kabir
Kentaro Kato
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2018
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-018-2392-4

Other articles of this Issue 1/2018

Malaria Journal 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine